3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
12
Fallopian Tube Neoplasms
8
Sarcoma
2
Neoplasms
2
Neoplasm Metastasis
2
Multi-centric Castleman's Disease
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Cancer Recurrent
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphadenopathy
1
Liposarcoma
1
Leiomyosarcoma
1
Hodgkin Disease
1
Histiocytoma, Malignant Fibrous
1
HIV Infections
1
Gliosarcoma
1
Glioblastoma
1
Fallopian Tube Mucinous Adenocarcinoma
1
Endometrial Neoplasms
1
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
liposomal doxorubicin
×
30 days
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled